Sierra oncology, inc. (SRRA)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss

-88,275

-53,335

-42,015

-47,867

-

-

-

Net loss

-

-

-

-

-53,260

-23,873

-6,832

Adjustments to reconcile net loss to net cash used in operating activities:
Non-cash restructuring charges

-

-

-

811

-

-

-

Stock-based compensation

-

-

-

-

-

-

22

Changes in fair value of warrant liabilities

20,926

-

-

-

17,443

1,380

202

Securities issuance obligation

10,485

-

-

-

-

-

-

Stock-based compensation

5,695

6,796

5,905

5,510

3,186

302

-

Warrant issuance costs

1,279

-

-

-

-

-

-

Term loan repayment fee

438

-

-

-

-

-

-

Depreciation and amortization

83

111

258

197

111

12

1

Noncash interest expense on short-term promissory notes and long-term note payable

-

-

-

-

-

-

2,760

Common stock issuance for milestone payment

-

-

-

-

-

-

57

Other

-161

68

-31

-15

-34

2

-

Changes in operating assets and liabilities:
Prepaid expenses and other assets

-336

1,341

115

362

1,087

531

10

Accrued, other and operating lease liabilities

-2,034

2,770

-

-

-

-

-

Accrued liabilities

-

-

990

-1,713

5,302

740

356

Accounts payable

-277

-48

-1,217

2,246

6

186

-89

Net cash used in operating activities

-51,183

-45,115

-36,163

-41,163

-

-

-

CASH FLOWS FROM INVESTING ACTIVITIES:
Accrued interest

-

-

-

-

-

-

-39

Net cash used in operating activities

-

-

-

-

-28,265

-21,786

-3,572

Purchase of property and equipment

39

118

92

214

414

187

2

Change in restricted cash

-

-

-

-

150

75

-

Proceeds from sale of property and equipment

-

-

-

43

-

-

-

Net cash used in investing activities

-39

-118

-92

-171

-

-

-

CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from public offering, net of offering costs

97,731

-

-

-

-

-

-

Payment of term loan and repayment fee

5,438

-

-

-

-

-

-

Proceeds from short-term convertible promissory notes

-

-

-

-

-

-

2,445

Proceeds from exercise of common stock options

445

180

166

211

18

305

25

Proceeds from sale of short-term investments

-

-

-

-

10,031

-

-

Purchase of short-term investments

-

-

-

-

21

10,020

-

Net cash used in investing activities

-

-

-

-

9,446

-10,282

-2

Proceeds from issuance of common stock upon follow-on offering, net of offering costs

-

45,996

27,422

-

-

-

-

Proceeds from issuance of term loan, net of issuance costs

-

4,955

-

-

-

-

-

Payment of deferred offering costs

-

-

-

15

3,389

316

-

Net cash provided by financing activities

92,738

51,131

27,588

196

-

-

-

Proceeds from issuance of common stock upon initial public offering, net of issuance costs

-

-

-

-

147,270

-

-

Proceeds from exercise of redeemable convertible preferred stock warrants

-

-

-

-

1,507

-

-

Proceeds from early exercise of stock options

-

-

-

-

13

100

-

Proceeds from issuance of redeemable convertible preferred stock, net of issuance costs

-

-

-

-

-

57,545

2,219

Repayment of stock subscription receivable

-

-

-

-

-

1,159

-

Net cash provided by financing activities

-

-

-

-

139,876

58,793

4,689

Effect of exchange rate changes on cash, cash equivalents and restricted cash

-34

-88

-4

-60

-

-

-

NET (DECREASE) IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH

41,482

5,810

-8,671

-41,198

-

-

-

Effect of exchange rate changes on cash and cash equivalents

-

-

-

-

-31

-

-

NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS

-

-

-

-

121,026

26,725

1,115

SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
Cash paid for (refund of) income taxes, net

-69

15

260

107

8

-

-

Cash paid for interest

336

87

-

-

-

-

-

Cash paid for interest

-

-

-

-

-

-

0

SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING INFORMATION:
Right-of-use asset obtained in exchange for operating lease obligation

771

-

-

-

-

-

-

Unpaid property and equipment in accrued and other liabilities

-

-

4

85

90

39

-

Unpaid deferred financing costs in accrued and other liabilities

268

-

-

-

-

-

-

Issuance of common stock warrant

-

116

-

-

-

-

-

Change in redemption value of redeemable convertible preferred stock

-

-

-

-

374,015

-

-

Change in redemption value of redeemable convertible preferred stock

-

-

-

-

-

-49,849

-5,713

Conversion of preferred stock to common stock

-

-

-

-

539,151

-

-

Issuance of redeemable convertible preferred stock on exercise of warrants

-

-

-

-

19,253

-

-

Offering costs included in accounts payable and accrued liabilities

-

-

-

-

154

233

-

Conversion of short-term convertible promissory notes and accrued interest into Series C redeemable convertible preferred stock

-

-

-

-

-

-

5,383

Issuance of preferred stock warrants with redeemable convertible preferred stock

-

-

-

-

-

-

57

Settlement of premium conversion derivative in redeemable convertible preferred stock

-

-

-

-

-

-

2,415